{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:43:23Z","timestamp":1792806203050,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabres.2026.113477","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:02:13Z","timestamp":1785538933000},"page":"113477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Estimated glomerular filtration rate slope and clinical outcomes: a narrative review"],"prefix":"10.1016","volume":"239","author":[{"given":"Fan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanhaier","family":"Abudoureheman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113477_b0005","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.diabres.2026.113477_b0010","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2026.113477_b0015","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2026.113477_b0020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2026.113477_b0025","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11897-024-00668-8","article-title":"Estimated glomerular filtration rate slope as an endpoint in cardiovascular trials","volume":"21","author":"Hamid","year":"2024","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.diabres.2026.113477_b0030","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2026.113477_b0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/jebm.12646","article-title":"The association between the eGFR slope and cardiorenal prognosis in patients with renoprotective treatments: a systematic review and meta-analysis","volume":"17","author":"Bai","year":"2024","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.diabres.2026.113477_b0040","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/8859678","article-title":"Is eGFR slope a novel predictor of chronic complications of type 2 diabetes mellitus? a systematic review and meta-analysis","volume":"2024","author":"Sartore","year":"2024","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.diabres.2026.113477_b0045","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2215\/CJN.0000000662","article-title":"Clinical implications of slope of GFR in clinical trials of CKD progression","volume":"20","author":"Greene","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2026.113477_b0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2215\/CJN.0000000000000050","article-title":"Evaluation of variation in the performance of GFR slope as a surrogate end point for kidney failure in clinical trials that differ by severity of CKD","volume":"18","author":"Collier","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2026.113477_b0055","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1007\/s00125-019-4948-4","article-title":"The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study","volume":"62","author":"Oshima","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2026.113477_b0060","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1111\/dom.15817","article-title":"Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: an analysis of the EXSCEL trial","volume":"26","author":"Oulhaj","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113477_b0065","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ehf2.15128","article-title":"eGFR slope as predictor of mortality in heart failure patients","volume":"12","author":"Verstreken","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.diabres.2026.113477_b0070","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1053\/j.ajkd.2025.01.011","article-title":"Association of estimated GFR slope and heart failure progression in older adults","volume":"85","author":"Kohansal","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2026.113477_b0075","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1681\/ASN.2015060688","article-title":"Past decline versus current eGFR and subsequent mortality risk","volume":"27","author":"Naimark","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2026.113477_b0080","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/HJH.0000000000004324","article-title":"eGFR slope and risk of cardiovascular, kidney, and mortality outcomes in hypertension: a longitudinal cohort study","volume":"44","author":"Oda","year":"2026","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabres.2026.113477_b0085","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfag089","article-title":"Estimated glomerular filtration rate slope and kidney outcomes in IgA nephropathy","author":"Sasaki","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabres.2026.113477_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110924","article-title":"Association of eGFR slope with all-cause mortality, macrovascular and microvascular outcomes in people with type 2 diabetes and early-stage chronic kidney disease","volume":"205","author":"Jin","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113477_b0095","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12882-021-02282-5","article-title":"Adverse outcomes associated with rapid linear and non-linear patterns of chronic kidney disease progression","volume":"22","author":"Ali","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.diabres.2026.113477_b0100","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.ajkd.2020.07.025","article-title":"Association between midlife obesity and kidney function trajectories: the atherosclerosis risk in communities (ARIC) study","volume":"77","author":"Yu","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2026.113477_b0105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2022.05.010","article-title":"Urate transporter ABCG2 function and asymptomatic hyperuricemia: a retrospective cohort study of CKD progression","volume":"81","author":"Ohashi","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2026.113477_b0110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1053\/j.ajkd.2025.01.010","article-title":": Time-updated estimated GFR variability is associated with mortality, cardiovascular disease, and end-stage kidney disease in patients with CKD: findings from the CRIC study","volume":"85","author":"Nishiwaki","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2026.113477_b0115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003825","article-title":"Long-term visit-to-visit blood pressure variability and renal function decline in patients with hypertension over 15years","volume":"5","author":"Chia","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabres.2026.113477_b0120","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113477_b0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113477_b0130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113477_b0135","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ndt\/gfac157","article-title":"Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study","volume":"38","author":"Ruilope","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabres.2026.113477_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110592","article-title":"Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials","volume":"198","author":"Yang","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113477_b0145","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2215\/CJN.0000000810","article-title":"Effects of dapagliflozin on progression of CKD according to different rates of Pretrial eGFR loss","volume":"20","author":"Heerspink","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2026.113477_b0150","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.kint.2024.05.024","article-title":"A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection","volume":"106","author":"Heerspink","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2026.113477_b0155","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1681\/ASN.2019010009","article-title":"Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2026.113477_b0160","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.kint.2024.06.007","article-title":"Clinical trial designs to assess treatment effects on glomerular filtration rate decline","volume":"106","author":"Heerspink","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2026.113477_b0165","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-024-02941-8","article-title":"A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials","volume":"30","author":"Kondo","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2026.113477_b0170","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.kint.2025.03.011","article-title":"Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpoint","volume":"107","author":"Little","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2026.113477_b0175","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/eurheartj\/ehab832","article-title":"Kidney function assessment and endpoint ascertainment in clinical trials","volume":"43","author":"Khan","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2026.113477_b0180","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamacardio.2021.5151","article-title":"Potential role and limitations of estimated glomerular filtration rate slope assessment in cardiovascular trials: a review","volume":"7","author":"Khan","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabres.2026.113477_b0185","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1373\/clinchem.2005.0525144","article-title":"Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program","volume":"52","author":"Myers","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.diabres.2026.113477_b0190","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1053\/ajkd.2002.32765","article-title":"Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate","volume":"39","author":"Coresh","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2026.113477_b0195","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113477_b0200","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function","volume":"369","author":"Shlipak","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113477_b0205","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1053\/j.ajkd.2013.03.027","article-title":"Update on cystatin C: incorporation into clinical practice","volume":"62","author":"Shlipak","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2026.113477_b0210","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jama.2015.0602","article-title":"Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review","volume":"313","author":"Levey","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2026.113477_b0215","first-page":"202","article-title":"Glutathione supplementation during cold ischemia does not confer early functional advantage in renal transplantation","volume":"70","author":"Polyak","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.diabres.2026.113477_b0220","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074216","article-title":"Advances in the management of chronic kidney disease","volume":"383","author":"Chen","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113477_b0225","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2021.03.007","article-title":"Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IGA nephropathy: an individual participant meta-analysis","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2026.113477_b0230","doi-asserted-by":"crossref","first-page":"i46","DOI":"10.1093\/ndt\/gfaf184","article-title":"What are the right endpoints to assess the effectiveness of new treatments for IgAN?","volume":"41","author":"Jongs","year":"2026","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.diabres.2026.113477_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1557813","article-title":"Surrogate endpoints in diabetic kidney disease: current perspectives and future directions","volume":"16","author":"Cao","year":"2025","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:16:40Z","timestamp":1792804600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726003979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"alternative-id":["S0168822726003979"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113477","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimated glomerular filtration rate slope and clinical outcomes: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113477"}}